Aligos Presents Promising Data For Pevifoscovir Sodium In Treating Hepatitis B
Aligos Therapeutics said it presented at the EASL 2026 congress positive results for pevifoscorvir sodium in chronic hepatitis B. The company reported Phase 1 long-term follow-up showing reduced HBV cccDNA, and Phase 2 B-SUPREME data indicating lower HBV/HBV RNA and HBV levels below 3,000 IU/mL in some HBsAg+ patients after 96 weeks monotherapy.
How this was made
The 30-second read
Why it matters
Positive congress data on HBV/HBV RNA and HBsAg reductions supports the functional-cure thesis and can increase expectations for ongoing Phase 2 combination results.
Market read
New clinical presentation data for ALGS’ HBV program is the direct catalyst and can drive trading activity around biotech risk appetite and functional-cure expectations.
What to watch
Key missing items are sample size, statistical significance, safety/tolerability, and whether combination regimens (with ASO such as ALG-170675) replicate monotherapy signals in a controlled way.
Background
Aligos is developing pevifoscorvir sodium (oral CAM-E) for chronic hepatitis B, targeting reduction of the cccDNA reservoir and exploring combinations with an ASO partner program.
Ticker impact
Aligos presented positive EASL 2026 data for pevifoscorvir sodium in chronic hepatitis B, including 96-week monotherapy follow-up and HBsAg/HBV reductions.
Likely modest-to-moderate upside bias on continued biotech momentum, with volatility tied to how investors interpret Phase 2/functional-cure signals.
The article cites multiple favorable endpoints (HBV/RNA declines, HBsAg reduction below 3,000 IU/mL) but provides no full trial details, statistical significance, or regulatory milestones beyond congress presentations.
Market effects
Strength in HBV capsid-modulator/CAM-E and potential combo strategy may improve sentiment toward other HBV functional-cure approaches and CAM-E/ASO platforms.
Limited direct regional linkage; impact mainly through global biotech sentiment around EASL.
HBV remains a large global market; durable biomarker declines can influence broader investor appetite for viral-hepatitis pipelines.
Counterpoint
Congress presentations can overstate clinical impact; investors may discount biomarker-driven results without clear virologic cure rates or confirmatory Phase 2/3 endpoints.
Key entities
- companyAligos Therapeutics Inc.
Presented positive EASL 2026 data for pevifoscorvir sodium in chronic hepatitis B, including 96-week monotherapy follow-up and HBsAg reduction.
- partnerAmoytop
Partnered on ALG-170675, an antisense oligonucleotide referenced as part of a potential functional-cure regimen.
